One of World’s Largest DNA Supply Agreements
Enables Diverse Product Development Across Multiple Industries
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA),
the leading horizontal platform for cell programming, today
announced a new supply agreement expanding the depth and breadth of
the collaboration between two of the leading organizations in the
synthetic biology ecosystem. The four-year agreement includes an
increased commitment by Ginkgo to purchase products from Twist,
with the option to access significantly more synthesis capacity to
meet Ginkgo’s anticipated growth. The partnership builds on a
previous supply agreement signed in 2017.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220405005337/en/
“We love to make investments alongside incredible partners like
Twist. Over the past four years, we ordered approximately one
billion base pairs of synthetic DNA from Twist, allowing us to test
hundreds of thousands of proteins across dozens of programs for our
customers, resulting in many completed programs spanning vaccine
manufacturing, food, flavor, fragrance and even cannabigerol
(CBG),” said Jason Kelly, CEO of Ginkgo. “As we grow our
capabilities to meet an increasing number and variety of customer
needs, we are excited to continue partnering with leading companies
in our ecosystem, which includes making sure we secure the high
volumes of DNA that Twist is well positioned to supply.”
“At Twist, we work in service of our customers, like Ginkgo, who
are changing the world for the better,” commented Emily M.
Leproust, Ph.D., CEO and co-founder of Twist. “Together, Twist and
Ginkgo facilitate new product development across multiple
industries, with Twist supplying the DNA and Ginkgo programming
cells. As the bioeconomy expands with new solutions to the grand
challenges facing all of us, we stand ready to deliver day by day,
with a vision as to how as an industry, we can truly drive positive
outcomes through diverse product solutions.”
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program
cells as easily as we can program computers. The company's platform
is enabling biotechnology applications across diverse markets, from
food and agriculture to industrial chemicals to pharmaceuticals.
Ginkgo has also actively supported a number of COVID-19 response
efforts, including K-12 pooled testing, vaccine manufacturing
optimization and therapeutics discovery. For more information,
visit www.ginkgobioworks.com.
Ginkgo Legal Notice Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding Ginkgo’s anticipated growth, anticipated
increased capabilities and supply agreement with Twist. These
forward-looking statements generally are identified by the words
"believe," "can," "project," "potential," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan,"
"may," "should," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the effect of Ginkgo’s business combination with
Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's
business relationships, performance, and business generally, (ii)
risks that the business combination disrupts current plans of
Ginkgo and potential difficulties in Ginkgo's employee retention,
(iii) the outcome of any legal proceedings that may be instituted
against Ginkgo related to its business combination with Soaring
Eagle, (iv) volatility in the price of Ginkgo's securities now that
it is a public company due to a variety of factors, including
changes in the competitive and highly regulated industries in which
Ginkgo operates and plans to operate, variations in performance
across competitors, changes in laws and regulations affecting
Ginkgo's business, changes in the combined capital structure and
expectations associated with increases in the number of shares
available for sale, (v) the ability to implement business plans,
forecasts, and other expectations after the completion of the
business combination, and identify and realize additional
opportunities, (vi) the risk of downturns in demand for products
using synthetic biology, (vii) the unpredictability of the duration
of the COVID-19 pandemic and the demand for COVID-19 testing and
the commercial viability of our COVID-19 testing business, and
(viii) changes to the biosecurity industry, including due to
advancements in technology, emerging competition and evolution in
industry demands, standards and regulations. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the "Risk Factors" section of Ginkgo's annual report on Form
10-K filed with the U.S. Securities and Exchange Commission (the
"SEC") on March 29, 2022 and other documents filed by Ginkgo from
time to time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q
filed with the Securities and Exchange Commission on February 9,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220405005337/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs Twist Bioscience abitting@twistbioscience.com
For Ginkgo Bioworks: press@ginkgobioworks.com
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Sep 2023 to Sep 2024